15.60 0.00 (0.00%)
After hours: 4:00PM EDT
|Bid||15.52 x 800|
|Ask||15.54 x 1300|
|Day's Range||15.01 - 15.65|
|52 Week Range||8.92 - 18.39|
|Beta (3Y Monthly)||0.14|
|PE Ratio (TTM)||445.71|
|Earnings Date||May 11, 2017 - May 12, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||25.33|
Generally speaking, investors are inspired to be stock pickers by the potential to find the big winners. You won't get...
ROCHESTER, Mich., Aug. 07, 2019 -- OptimizeRx Corp. (NASDAQ: OPRX), a leading provider of digital health messaging for the pharmaceutical industry, reported results for the.
OptimizeRx's (OPRX) second-quarter 2019 results are likely to benefit from increased sales of core financial and brand messaging products.
OptimizeRx (OPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ROCHESTER, Mich., July 24, 2019 -- OptimizeRx Corp. (Nasdaq: OPRX), a leading platform for digital health messaging in the pharmaceutical industry, will hold a conference call.
ROCHESTER, Mich., July 23, 2019 -- OptimizeRx Corp. (Nasdaq: OPRX), a leading platform for digital health messaging in the pharmaceutical industry, announced a new partnership.
The big shareholder groups in OptimizeRx Corporation (NASDAQ:OPRX) have power over the company. Institutions often own...
The Russell 2000 Index is a small-cap stock market index that includes the bottom 2,000 companies found in the Russell 3000 index. The Russell Microcap Index includes the 1,000 smallest securities found ...
OptimizeRx Corp. (OPRX), a leading platform for digital health messaging in the pharmaceutical industry, is expected to join the Russell Microcap® and 3000® Indexes at the conclusion of the 2019 Russell indexes annual reconstitution, effective after the U.S. market opens on July 1, according to a preliminary list of additions posted June 21. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes. “We are honored to be included in the Russell Indexes,” said OptimizeRx CEO, William Febbo.
The Zacks Analyst Blog Highlights: Malibu Boats, MEDIFAST, OptimizeRx, Synergy Resources and Pioneer Natural
OptimizeRx Corp. (OPRX), a leading platform for digital health messaging in the pharmaceutical industry, has been invited to participate in the ROTH London Conference being held on June 17-19, 2019 at the Dorchester Hotel in London, U.K. The ROTH London Conference will give investors extensive interaction and one-on-one/small group meetings with management teams from about 50 small/mid-cap companies in the technology, cleantech and industrial sectors, and provide in-depth insights into each of them.
Open Text (OTEX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
OptimizeRx Corp. (OPRX), a leading platform for digital health messaging in the pharmaceutical industry, has added three senior sales executives to its rapidly growing commercial team. The new hires demonstrate the company’s focus on driving growth and expanding its enterprise-level offerings. “Todd, Eze and Adam are each proven commercial sales leaders with strong records of delivering enterprise-level solutions and addressing unmet needs across the care continuum,” said Steve Silvestro, the company’s recently added chief commercial officer. According to a recent PWC study, 52 percent of consumers with a high deductible health plan say it would be hard to meet their deductible.
The Zacks Analyst Blog Highlights: OptimizeRx, eHealth, Strategic Education, Hibbett Sports and PC-Tel
OptimizeRx Corporation (OPRX), a leading provider of digital health messaging for the pharmaceutical industry, today announced the pricing of the previously announced underwritten public offering of 1,538,500 shares of its common stock, at a public offering price of $13.00 per share. The gross proceeds to OptimizeRx from the offering, before deducting the underwriting discounts and commissions and estimated offering expenses payable by OptimizeRx, are expected to be approximately $20.0 million. In connection with the offering, OptimizeRx granted the underwriters a 30-day option to purchase up to an additional 230,775 shares of its common stock at the public offering price, less the underwriting discount and commissions.
Powell's statement is in sharp contrast to his aggressive monetary stance in 2018 and a steady monetary policy for 2019, which he reaffirmed last month.